Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Acute lymphoblastic leukaemia (ALL) is a fast-growing blood cancer affecting white blood cells. For some adults, standard therapies do not work or the disease comes back. This trial tests an experimental treatment called UCART22. UCART22 is made from healthy donor immune cells that are genetically adapted in a laboratory. These cells are trained to spot and attack a specific protein (called CD22) found on leukaemia cells. Because they come from donors, they are ready to use without long delays. Before receiving UCART22, patients receive brief chemotherapy to help clear space in the body so the new cells can work properly. The study aims to find safe doses, observe side effects, and check if the treatment can clear the cancer, potentially helping patients become well enough for a future stem cell transplant.
At a glance
What is this study about?
Leukaemia is a cancer of the blood and bone marrow. In B-cell acute lymphoblastic leukaemia (B-ALL), the body produces too many abnormal white blood cells. While standard treatments such as chemotherapy work well for many people, the cancer can sometimes return (relapse) or resist treatment (refractory). When standard options are exhausted, doctors look for advanced ways to help the immune system fight the cancer.
This trial investigates an innovative type of immunotherapy known as UCART22. In standard cell therapies, a patient's own cells must be collected and altered, which can take weeks. UCART22 uses healthy cells from donors that are modified ahead of time. These cells are designed to recognise CD22, a target found on the surface of most B-cell leukaemia cells, and destroy them.
The main purpose of this study is to discover the safest and most effective dose of UCART22. Researchers also want to track how long the modified cells survive in the body and see whether they can clear the leukaemia completely. For some participants, clearing the leukaemia might make them eligible for a stem cell transplant, which could offer longer-term protection against the disease.
Key takeaways
- Tests an 'off-the-shelf' donor cell therapy (UCART22) for hard-to-treat B-cell leukaemia.
- Aimed at adults aged 18 and over whose leukaemia has returned or stopped responding to past treatments.
- Involves preparatory chemotherapy followed by a hospital stay for close monitoring.
- Aims to find a safe dose and see if the treatment can clear cancer cells.
- Taking part is entirely voluntary, and you can withdraw at any time.
Who may be eligible?
This trial is open to adults aged 18 and older who have B-cell acute lymphoblastic leukaemia. To be considered, a person's cancer cells must test positive for a protein marker called CD22. Your medical team can confirm this with standard laboratory tests.
The study is specifically designed for people whose leukaemia has returned after earlier treatment or has not responded to standard therapies. Patients should be well enough to carry out everyday activities and manage hospital visits.
You may not be eligible if you have certain active infections, severe heart or kidney conditions, or if you are pregnant or breastfeeding. Your hospital specialist will carefully review your full medical history to see if this trial is safe and appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- You are aged 18 or older.
- You have been diagnosed with B-cell acute lymphoblastic leukaemia.
- Your leukaemia has returned or has not responded to previous treatments.
- Your leukaemia cells test positive for the CD22 marker.
- You are able to stay in hospital for several weeks for close monitoring.
What does participation involve?
Taking part begins with screening tests, such as blood tests and bone marrow samples, to make sure the trial is safe for you. If you join, you will first receive a few days of chemotherapy drugs through a drip. This temporary treatment clears space in your immune system so the donor cells can multiply. You will then receive the UCART22 cells as an intravenous infusion. Because side effects can happen quickly, you will stay in hospital for close observation for a few weeks. After returning home, you will attend regular clinic visits over several months to check your blood, monitor recovery, and see how the cancer is responding. Long-term follow-up visits will continue to track your health.
Potential risks and benefits
Locations (3)
- —UnverifiedFrance
- —UnverifiedItaly
- —UnverifiedSpain
Common questions
What makes UCART22 different from other CAR T-cell treatments?
Most CAR T-cell therapies use your own blood cells, which must be collected and modified over several weeks. UCART22 uses healthy donor cells prepared in advance, meaning treatment can begin much sooner.
Will I have to stay in hospital?
Yes. You will need to stay in hospital during the chemotherapy and for a few weeks after receiving UCART22 so doctors can closely monitor your safety and manage any side effects.
What is the CD22 marker?
CD22 is a protein found on the surface of certain white blood cells and B-cell leukaemia cells. The trial treatment is specially engineered to lock onto this protein to destroy the cancer cells.
Can I leave the study if I change my mind?
Yes. You are completely free to leave the trial at any point. Your decision will not change the standard of medical care or support you receive from your doctors.
Does taking part cost anything?
No. The trial medication and all study-related tests are provided free of charge, though you should check with the hospital team regarding travel cost support.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.